PR
AUPH icon

PSP Research’s Aurinia Pharmaceuticals AUPH Stock Holding History

PSP Research’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$509K Hold
30,000
– – 0.27% 17
2026
Q1 		$445K Sell
30,000
-3,953
-12% -$57.8K 0.31% 38
2025
Q4 		$542K Buy
+33,953
New +$481K 0.47% 20

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PSP Research's AUPH Position: Q2 2026 in Review

PSP Research held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2026 at 30,000 shares worth $509K. The position accounts for 0.27% of the portfolio, ranked #17.

PSP Research first reported a position in AUPH in Q4 2025 and has held it in 3 quarters since. The position peaked at $542K in Q4 2025. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • PSP Research held 30,000 shares of Aurinia Pharmaceuticals worth $509K as of Q2 2026.
  • PSP Research left its Aurinia Pharmaceuticals share count unchanged in Q2 2026.
  • Aurinia Pharmaceuticals made up 0.27% of PSP Research's portfolio in Q2 2026, its #17 holding.
  • PSP Research first reported a position in Aurinia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Aurinia Pharmaceuticals position peaked at $542K in Q4 2025.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.